Glossary

Product Availability

We sell a number of approved interventional medicine products in territories around the world.
Product Availability Map

Please find explanations for common terms used below:

 

Apoptosis
Programmed cell death or “cell suicide”. Apoptosis normally occurs as part of the body’s natural growth, maintenance and tissue renewal processes. Under certain circumstances, e.g. in the tissue surrounding a brain haemorrhage, this process can become uncontrolled and lead to widespread tissue cell death.
Arteriovenous malformation A knot of distended blood vessels often overlying and compressing the surface of the brain.
CE Mark A European standard for medical devices, a CE Mark indicates that a device meets the requirements of the Medical Device Directive and appropriate Quality System standards.
Chemoembolisation Embolisation incorporating a chemotherapy drug
CIRSE The Cardiovascular and Interventional Radiological Society of Europe
Conventional TACE Trans-Arterial Chemo-Embolisation - a procedure whereby a chemotherapeutic agent is mixed into slurry and injected via a catheter, locally at a tumour site.

DC Bead®

DC Bead® is an embolic Drug-Eluting Bead capable of loading and releasing in a controlled manner chemotherapeutic agents.
DC BeadM1 DC BeadM1has been developed with a narrower distribution and offers the proven benefits of DC Bead® to more patients.

DEBDOX

Treatment involving DC Bead® with doxorubicin

DEBIRI Treatment involving the DC Bead® with Irinotecan
Doxorubicin A widely used chemotherapeutic agent for the treatment of a large number of cancers. It is a powerful cytotoxic drug that is not cell cycle specific.
Drug-Eluting Beads Polymer embolisation microspheres designed to load and elute drugs.
Drug-Eluting Irinotecan Bead Clinical Trials A family of clinical trials sponsored by Biocompatibles for the evaluation of Drug-Eluting Beads for the treatment of hepatic colorectal metastases.
Embolisation The introduction of material to reduce or completely obstruct bloodflow.
FDA The United States Food and Drug Administration, which regulates drugs and medical devices.
FOLFIRI A chemotherapy regimen for the treatment of colorectal cancer, made up of the drug FOLinic Acid (Leucovorin), Fluorouracil (5-FU) and IRInotecan (Camptosar).
HCC Hepatocellular carcinoma, primary tumour of the liver.
Hepatic colorectal metastases Colorectal cancer that has spread to the liver.
Hypervascular tumour A growth of tissue with an abnormally increased blood supply which may be malignant or benign.
IDE Investigational Device Exemption - The approval by the FDA to carry out a clinical trial in the US with an unapproved device.
Interventional Oncology Interventional oncology is the treatment of cancer and cancer-related problems using minimally invasive, targeted treatments performed under imaging guidance.
Irinotecan A widely used chemotherapeutic agent for the treatment of colorectal cancer. It is a topoisomerase I inhibitor that interferes with DNA replication during cell division, leading to cell death.

LC Bead®

LC Bead® is intended for the embolisation of hypervascularised tumours and arteriovenous malformation.  LC Bead® has 510k clearance from the FDA.

LC BeadM1 LC BeadM1 has been developed with a narrower distribution and offers the benefits of LC Bead® to more patients.
Metastatic disease The spread of a cancer from its original site (primary) to other locations within the body (secondary). In the case of colorectal cancer, the liver is the most common site of secondary tumours.
mCRC Metastatic Colorectal Cancer is cancer of the colon or rectum that has spread, or metastasised to other parts of the body, such as the liver or lung.
Nexavar® (sorafenib) Nexavar is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
PARAGON Bead™ Biocompatibles' proprietary irinotecan HCl, drug-eluting bead.
PARAGON I PARAGON I is in hepatic colorectal metastases; Randomised controlled trial; Safety & Efficacy; 70 patients; multi-centre; United States; FDA approved
PRECISION Bead™ Biocompatibles' proprietary Drug-Eluting Bead product containing doxorubicin.
PRECISION Clinical Trials A family of clinical trials for the evaluation of the Drug-Eluting Beads with doxorubicin.
PRECISION TACE The use of either PRECISION Bead or DC Bead in the TACE procedure. PRECISION TACE results in a lower systemic drug exposure and more drug at the tumour site.
Pre-loaded Bead A Drug-Eluting Bead incorporating a drug which has been loaded into the Bead in Biocompatibles' facility.
Systemic chemotherapy Treatment with anticancer drugs that travel through the bloodstream, reaching and affecting cells all over the body.
Tumour Response

A measurement of the effect of a treatment on a tumour:
Complete Response - Disappearance of the targeted lesion

Partial Response - Greater than 30-50% (depending on evaluation method) reduction in the targeted lesion

Progressive Disease - Greater than 20-25% (depending on evaluation method) increase in the targeted lesion

Stable Disease - All other cases

Objective Response - Complete and Partial Response